sotevtamab   Click here for help

GtoPdb Ligand ID: 11763

Synonyms: 16B5 [1] | AB-16B5 | AB-sCLU mAb | AB16B5
Compound class: Antibody
Comment: Sotevtamab (AB-16B5) is a humanized IgG2 antibody against secreted clusterin. It was developed by Alethia Biotherapeutics for anti-cancer potential. Peptide sequences of the heavy and light chains of the antibody are claimed in patent WO2011063523A1 [1], via which sotevtamab can be linked to the antibody designated as humanised 16B5. Sotevtamab is expected to inhibit clusterin-induced epithelial to mesenchymal transition, as a mechanism to both reduce tumour invasion and augment the response to standard of care chemotherapy.
Click here for help
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
11666 sotevtamab
Synonyms Click here for help
16B5 [1] | AB-16B5 | AB-sCLU mAb | AB16B5
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1170
Other databases
GtoPdb PubChem SID 458923798
Search PubMed clinical trials sotevtamab
Search PubMed titles sotevtamab
Search PubMed titles/abstracts sotevtamab